Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II study of TTI-621 monotherapy in patients with second line peripheral T-cell lymphoma

Next Previous
X
Search
Trial Profile

Phase Ib/II study of TTI-621 monotherapy in patients with second line peripheral T-cell lymphoma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ontorpacept (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Trillium Therapeutics

    • Most Recent Events

    • 05 May 2021 New trial record
    • 28 Apr 2021 According to a Trillium Therapeutics media release, the company plans to initiate this study in 3Q 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top